A ‘Blood Pressure Test’ For Dementia

Neuroscience Innovator Looks At Early Diagnosis From New Angle

The attention accorded to dementia, MCI and degenerative brain conditions has been slow to reach the levels given to the more visibly-quantifiable conditions, such as cardiovascular disease and oncology. But earlier detection of cognitive impairment is a priority, despite therapies not yet being available to halt or reverse the conditions. Playing its part to push back the boundaries is Cognetivity Neurosciences, a London-based company with an innovative tool that uses AI to test subjects for the early signs of dementia.

Brain decline and dementia or aging as memory loss concept for brain cancer decay or an Alzheimer's disease with old rusting mechanical gears and cog wheels in the shape of a human head with rust.
Cognetivity is focused on technology to help identify dementia at the earliest stages • Source: Shutterstock

Fresh approaches to early testing for dementia are increasingly common, but the resulting technology has tended to fall short in terms of results. London-based Cognetivity Neurosciences Ltd. has been developing a compelling solution, the ICA (Integrated Cognitive Assessment) test using natural images that are presented quickly to participants who are asked to accurately indicate whether they have seen a pre-specified image category. The test can be performed on an iPAD, potentially in any setting. The viewed images are processed in the visual cortex, a brain region associated with the earliest signs of neurodegeneration in conditions such as Alzheimer's disease (AD), and are translated to movement in the motor cortex, allowing evaluations to be made based on comparisons with an accurate dataset of clinically-diagnosed subjects. It is a technology that the company believes has applications in and beyond the clinical setting.

The involvement of Cognetivity, a Cambridge spin-out, in the technology began when one of its founders, Dr Seyed-Mahdi Khaligh-Razavi, a...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Innovation

More from In Vivo